Learner Notification

Society of Gynecologic Oncology 2022 Allied Health Professionals Meeting Live: October 14 – 16, 2022 Enduring: through December 31, 2022 Chicago, IL & Online

Acknowledgement of Financial Commercial Support

GSK Eisai

Seagen

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Joint Accreditation Statement



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Society of Gynecologic Oncology (SGO). Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME) Credit Designation

Amedco LLC designates this **live activity / enduring material** for a maximum of **12.0** Live / **13.75** Enduring AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

PAs may claim a maximum of 12.0 Live / 13.75 Enduring Category 1 credits for completing this activity.

Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 12.0 Live / 13.75 Enduring ANCC contact hours.

Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

Amedco LLC designates this activity for a maximum of 12.0 Live / 13.75 Enduring knowledge-based CPE contact hours.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

Objectives - After Attending This Program You Should Be Able To

- 1. Identify different types of chemotherapy side effects and best practice for management.
- 2. Compare the options for PARP inhibitors and discuss the trials which have led to the use of them.
- 3. Discuss HPV and the implications surrounding diagnosis and treatment management.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

| First | Last | Role | Commercial Interest |
|-------|------|------|---------------------|
| | | | |

| Sarah | Ackroyd | Speaker | NA |
|-----------|------------|---------------------------------------|---|
| Allison | Asante | Speaker | AstraZeneca:Consultant |
| Tristan | Bilash | Speaker | NA |
| Kerry | Buicko | Planning Committee | NA |
| Kristen | Carpenter | Speaker | NA |
| Ilana | Cass | Speaker | NA |
| Josh | Cohen | Planning Committee | NA |
| Christine | Deskovich | Speaker | Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.:Consultant |
| Nicole | Dreibelbis | Planner, Chair, Planning Committee | NA |
| Terri | Earles | Planning Committee | NA |
| Emily | Hinchcliff | Speaker | NA |
| Sarah | Irish | Planning Committee | NA |
| Joshua | Kesterson | Speaker | NA |
| MEGAN | LANIGAN | Speaker | NA |
| Kathleen | Lutz | Speaker | NA |
| Kathryn | Lyle | Planning Committee | Haymarket Medical Education:Speakers Bureau,PRIME Education:Speakers Bureau |
| Katherine | Mahar | Planning Committee | NA |
| Melissa | Mark | Speaker | NA |
| Kathryn | Mills | Speaker | Stryker:Consultant |
| Amanda | Nickles | Speaker | Onconova:Scientific/Medical Advisory Board Member,Eisai:Scientific/Medical |
| | Fader | | Advisory Board Member |
| Tracy | Sandstrom | CE Coordinator | NA |
| Stacey | Shields | Speaker | Pfizer:Stock Shareholder |
| Stephanie | Sullivan | Planner | NA |
| Lindsay | Tedder | Planning Committee | NA |
| Mary | Towner | Speaker | NA |
| Robert | Wenham | Speaker | Merck:Research Grant Overall Principal Investigator,Sonnet |
| | | | Biotherapeutics:Scientific/Medical Advisory Board Member,Eisai:Research Grant Site |
| | | | Principal Investigator, Eisai: Consultant, Regeneron: Research Grant Site Principal |
| | | | Investigator, Regeneron: Consultant, Seagen: Consultant, Seagen: Scientific/Medical |
| | | | Advisory Board Member, Shattuck Labs: Consultant, Tesaro: Scientific/Medical |
| | | | Advisory Board Member, On Target Labs: Research Grant Site Principal |
| | | | Investigator,Ovation Diagnostics:Stock Shareholder |
| Erica | Weston | Speaker | NA |